JW홀딩스

096760KOSPI기타 금융업

65.3 / 100

Reference Date: 2026-04-13

Financial Score25.0 / 40

News Sentiment15.3 / 25

Momentum13.0 / 20

Disclosure12.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

JW Holdings is a holding company established in 2007 through a spin-off from JW Chungwa Pharmaceutical, overseeing overseas operations and management services for its subsidiaries. In 2025, its revenue decreased by 6.3% to 933 billion won, with key products including nutrient solutions, penem antibiotics, and itraconazole. Major subsidiaries include JW Chungwa Pharmaceutical, JW Shin Yak, and JW Life Science, producing pharmaceuticals, medical devices, and infusion solutions.

Number of Employees

128people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

2.67Industry Average 10.018.0Point

Half of industry avg (excellent)

PBR

0.52Industry Average 0.482.5Point

Higher than industry avg (caution)

ROE

20.70Industry Average 5.517.0Point

3.8x industry avg (excellent)

Debt Ratio

30.24Industry Average 19.360.5Point

1.6x industry avg (risky)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.4% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲7.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 19.3% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 2Neutral 8Negative 0Average Sentiment Score 62.5

Positive
JW홀딩스, 기업가치 제고 계획 공시…배당성향 25% 목표
JW홀딩스가 배당성향 25%를 목표로 하는 기업가치 제고 계획을 공시하며 주주환원 정책을 강화할 방침을 밝혔습니다.
Positive
새 둥지 튼 솔리더스인베스트…김정현 체제 유지에 무게 [넘버스]
JW홀딩스가 솔리더스인베스트먼트를 인수하며 기존 경영 체제를 유지할 가능성이 높아 펀드 운용의 안정성을 확보할 것으로 예상됩니다.
Neutral
차바이오그룹 비핵심 계열사 정리…“3대 사업 집중”
차바이오그룹이 비핵심 계열사 및 투자 자산을 정리하며 세포·유전자치료제(CGT)·AI 헬스케어 등 3대 핵심 사업에 집중하고 있습니다.

Detailed Momentum

52-week position8.0Point

Near 52w high (80%, uptrend)

Current 4,175Won52-week high 4,47052-week low 2,985

1-month return3.0Point

1m 0.72% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 1Neutral 9Negative 0

Neutral투자판단관련주요경영사항(자회사의 주요경영사항)2026-04-08
Neutral최대주주등소유주식변동신고서2026-04-07
Neutral주식등의대량보유상황보고서(일반)2026-04-07
Neutral기업가치제고계획(자율공시)2026-03-27
Neutral정기주주총회결과2026-03-26